Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of RC1416 Injection in Patients With Moderate to Severe Asthma

NCT06911866 is registered in ClinicalTrials.gov with Nanjing RegeneCore Biotech Co., Ltd. as lead sponsor.

NCT NCT06911866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of RC1416 Injection in Patients With Moderate to Severe Asthma
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2024
Completion date
September 25, 2025
Enrollment
40 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe asthma